Wockhardt Limited
WOCKPHARMA
Rangering i aksjer
#4533
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical... Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
Aksjekurs
$20.65
Markedsverdi
$3.36B
Endring (1 dag)
-1.84%
Endring (1 år)
32.42%
Land
IN
Handel Wockhardt Limited (WOCKPHARMA)
Kategori
Healthcare
Antall utestående aksjer for Wockhardt Limited (WOCKPHARMA)
Antall utestående aksjer per June 2026: 162.49M
Ifølge Wockhardt Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 162.49M. Ved slutten av March 2024 hadde selskapet 144.25M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Wockhardt Limited (WOCKPHARMA) fra 2004 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 162.49M | 4.41% |
| 2025 | 155.63M | 7.89% |
| 2024 | 144.25M | 0.13% |
| 2023 | 144.06M | 19.50% |
| 2022 | 120.55M | 0.31% |
| 2021 | 120.19M | 0.03% |
| 2020 | 120.15M | 0.05% |
| 2019 | 120.09M | 8.60% |
| 2018 | 110.58M | 0.06% |
| 2017 | 110.51M | -0.60% |
| 2016 | 111.18M | -0.08% |
| 2015 | 111.27M | 0.20% |
| 2014 | 111.04M | -0.15% |
| 2013 | 111.21M | -6.35% |
| 2012 | 118.76M | 0.00% |
| 2011 | 118.76M | 0.00% |
| 2010 | 118.76M | 0.00% |
| 2008 | 118.76M | 0.00% |
| 2007 | 118.76M | 0.02% |
| 2006 | 118.74M | 0.24% |
| 2005 | 118.46M | 0.00% |
| 2004 | 118.46M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 445.06M | 173.90% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 105.38M | -35.15% |
US
|
